Mizuho raised the firm’s price target on Neumora Therapeutics (NMRA) to $6 from $5 and keeps an Outperform rating on the shares after the company made several announcements, highlighted by positive Phase 1b signal-seeking results for NMRA-511 in Alzheimer’s disease agitation. Better results seen in a pre-specified subset of AD patients with elevated anxiety is “an encouraging finding,” the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NMRA:
- Neumora (NMRA-511): Encouraging Early Alzheimer’s Agitation Data but Mixed V1a History and Valuation Keep Risk-Reward Balanced at Hold
- Positive Risk-Reward on Neumora as NMRA-511 Emerges as a Differentiated Therapy for Alzheimer’s Agitation, Supporting Buy Rating and $18 Target
- Neumora reports promising Phase 1b results in Alzheimer’s agitation
- Neumora Therapeutics announces results from NMRA-511 Phase 1b study
- Neumora Therapeutics highlights 2026 pipeline strategy